drugset / Trial / NCT00570726

Treatment of Failing Blebs With Ranibizumab

NCT00570726

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.

Timeline

Start
2000-06
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody

Indications